Targeting the SAGA and ATAC transcriptional coactivator complexes in MYC-driven cancers

Targeting epigenetic regulators such as histone modifying enzymes provides novel strategies for cancer therapy. The GCN5 lysine acetyltransferase (KAT) functions together with MYC both during normal development and in oncogenesis. As transcription factors, MYC family members are difficult to target with small molecule inhibitors, but the acetyltransferase domain and the bromodomain in GCN5 might provide alternative targets for disruption of MYC-driven functions. GCN5 is part of two distinct multiprotein histone modifying complexes, SAGA and ATAC. This review summarizes key findings on the roles of SAGA and ATAC in embryo development and in cancer, to better understand the functional relationships of these complexes with MYC family members, as well as their future potential as therapeutic targets.